VEGFA and glioblastoma: Also, dual inhibition of Ang-2/VEGF with a bispecific anti-Ang2/VEGFA antibody (CrossMab, A2V) prolongs the survival of patients and animal models of glioblastoma and sarcoma [23, 57, 65].